Fintech

Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026

Prnewswire·March 27, 2026 at 12:39 PM

/PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

Kalshi sued over alleged illegal gambling
PYMNTS
Coinbase Fixes Unwanted Prediction Market Notifications
PYMNTS
AI Risks Sink Cybersecurity Stocks
PYMNTS
AI upgrades Hollywood's classic films
PYMNTS

Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026

Kalshi sued over alleged illegal gambling

Coinbase Fixes Unwanted Prediction Market Notifications

AI Risks Sink Cybersecurity Stocks

AI upgrades Hollywood's classic films